Side effect of fluoropyrimidine-based chemoRT for rectal cancer – Memorial Sloan Kettering Radiation Oncology

Memorial Sloan Kettering Radiation Oncology shared on X:

“This nurse-led multidisciplinary collaboration discusses a rare but (likely underreported) side effect of fluoropyrimidine-based chemoRT for rectal cancer, colorectal cancer. This is an important QOL issue often assumed to be a radiation toxicity but driven by capecitabine.”

Read further.
Source: Memorial Sloan Kettering Radiation Oncology/X